12:00 AM
 | 
Feb 02, 2009
 |  BioCentury  |  Strategy

Limbo dancing

Pfizer Inc.'s decision to acquire Wyeth rippled quickly through the biotech industry, as Crucell N.V. announced that Wyeth withdrew from discussions regarding a potential combination of the two companies. While most of Wyeth's partners will have to wait and see if they are affected, looking at the disease targets that Pfizer has already identified as strategically important indicates that some Wyeth partners are sitting more comfortably than others.

Last month, Crucell disclosed it was in friendly discussions about a possible acquisition by Wyeth. The pharma had previously licensed Crucell's PER.C6 cell line and AdVac recombinant adenoviral vector technology, and last year the companies partnered to develop an undisclosed vaccine (see BioCentury, Jan. 12).

Edwin Moses, chairman and CEO of Ablynx N.V., said he is confident that Ablynx's partnership with Wyeth will survive acquisition. Indeed, he said he believes the acquisition of Wyeth could provide an entrée into Pfizer for Ablynx's Nanobody technology platform. "To date, we have not engaged deeply with Pfizer on Nanobodies - this acquisition should provide an opportunity to showcase our technology to the biggest pharma in the world," Moses told BioCentury.

Under a 2006 deal,...

Read the full 942 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >